뉴클레오티드 시장 : 질소 염기별, 용도별, 기술별, 제품별 - 세계 예측(2023-2032년)

Global Nucleotides Market will grow at a 6.3% CAGR between 2023 and 2032, owing to rapid advances in genomic research and the expanding landscape of personalized medicine. As genomics becomes increasingly pivotal in understanding and treating diseases, the demand for nucleotide-based products will surge. Nucleotides play a crucial role in genetic sequencing and therapeutic applications, creating a symbiotic relationship with the burgeoning field of personalized medicine. This convergence of genomic breakthroughs and personalized healthcare is a major driver, steering the nucleotides industry towards significant growth.

Companies are broadening their presence through collaborations and active participation in genomic research, focusing on the development of personalized medicines rooted in nucleotide-based innovations and showcasing a commitment to evolving healthcare solutions. For instance, in 2023, Agilent Technologies Inc. entered into a partnership with Quest Diagnostics, a global leader in diagnostic information services. This collaboration facilitates widespread access to the Agilent Resolution ctDx FIRST liquid biopsy next-gen sequencing test for healthcare providers and patients across the United States.

The nucleotides industry is fragmented based on nitrogenous base, technology, and region.

The pyrimidines segment will capture a significant revenue share by 2032, driven by the pivotal role of pyrimidines in DNA and RNA structures, making them essential components in various biological processes. Growing applications in pharmaceuticals, agriculture, and biotechnology contribute to the segment's prominence. Pyrimidines' versatility and wide-ranging utility will position them as a key driver in nucleotide-based products. As the demand for nucleotides continues to surge across diverse industries, the pyrimidines segment will be a key player in shaping the market landscape.

The SNP by pyrosequencing segment will achieve remarkable nucleotides market share by 2032, attributed to the method's precision and efficiency in identifying single nucleotide polymorphisms. As demand for personalized medicine and genetic research grows, SNP by pyrosequencing will gain prominence. Its accuracy in decoding nucleotide sequences will contribute to its preference in genotyping applications. With ongoing advancements in genomic analysis, this segment will stay at the forefront of the nucleotides industry, reflecting its pivotal role in genetic investigations.

Europe nucleotides industry will register a notable CAGR during 2023 and 2032, propelled by the region's robust research and development activities, particularly in the pharmaceutical and biotechnology sectors. In addition, Europe's stringent quality standards and emphasis on innovation contribute to its leading position in nucleotide-related products. The growing awareness of the nutritional significance of nucleotides, combined with a focus on cutting-edge technology, will position Europe as a major contributor to shaping the nucleotides industry outlook.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Covid-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Nucleotides industry 360 degree synopsis, 2018 - 2032 (USD Million)
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Nitrogenous base trends
  • 2.1.4 Application trends
  • 2.1.5 Technology trends
  • 2.1.6 Product trends

Chapter 3 Nucleotides Industry Insights

• 3.1 Industry landscape, 2018 - 2032 (USD Million)
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising demand for nucleotide-based therapeutics
    • 3.2.1.2 Increased research in genomics and molecular biology
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with nucleotide synthesis
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
  • 3.3.1 By nitrogenous base
  • 3.3.2 By application
  • 3.3.3 By technology
  • 3.3.4 By product
• 3.4 COVID-19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive analysis of major market players, 2022
• 4.4 Competitive positioning matrix, 2022
• 4.5 Strategic dashboard, 2022

Chapter 5 Nucleotides Market Estimates and Forecast, By Nitrogenous Base, 2018-2032 (USD Million)

• 5.1 Key trends, by nitrogenous base
• 5.2 Purine
• 5.3 Pyrimidine

Chapter 6 Nucleotides Market Estimates and Forecast, By Application, 2018-2032 (USD Million)

• 6.1 Key trends, by application
• 6.2 Diagnostics research
• 6.3 Pharmaceuticals
• 6.4 Other applications

Chapter 7 Nucleotides Market Estimates and Forecast, By Technology, 2018-2032 (USD Million)

• 7.1 Key trends, by technology
• 7.2 TaqMan allelic discrimination
• 7.3 SNP by pyrosequencing
• 7.4 Gene chips & microarrays
• 7.5 Other technologies

Chapter 8 Nucleotides Market Estimates and Forecast, By Product, 2018-2032 (USD Million)

• 8.1 Key trends, by product
• 8.2 Deoxynucleotides
• 8.3 Ribonucleotides
• 8.4 Labelled nucleotides
• 8.5 Dideoxy nucleotides

Chapter 9 Nucleotides Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Nanjing Bio Together Co., Ltd.
• 10.2 Agilent Technologies
• 10.3 F. Hoffmann-La Roche Ltd. (CustomBiotech)
• 10.4 CJ CHEILJEDANG CORP.
• 10.5 DAESANG
• 10.6 Jena Bioscience GmbH
• 10.7 MEIHUA HOLDINGS GROUP CO. LTD
• 10.8 Promega Corporation
• 10.9 STAR LAKE BIOSCIENCE
• 10.10 Thermo Fisher Scientific Inc.